Peptide
IGF-1 LR3
Also known as
Long R3 IGF-1 · Long Arg3 IGF-1 · Long-R3-IGF-I · LONG® R³ IGF-I (cell-culture reagent class) · IGF1 LR3 · IGF-1 Long R3 · LR3 IGF-1 · LR3-IGF-1 · Long arginine 3-IGF-1 · IGF-1
Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.
What it is
| Modified growth factor | An altered 83-amino-acid IGF-1 research protein discussed for muscle fullness, growth and recovery. It is different from prescription mecasermin, HGH and IGF-1 DES. |
|---|---|
| Routes and targeting | The record describes subcutaneous and intramuscular injections. Site-injection discussion does not establish activity confined to one muscle. |
Notes
An altered 83-amino-acid IGF-1 protein. Native IGF-1 has 70 amino acids. LR3 adds 13 and changes the third to arginine. A laboratory reagent or physique-use vial is different from prescription mecasermin and HGH. Human IGF-I LR3 Recombinant Protein, PeproTech (Official context · Accessed 2026-09-30)
SubQ and IM are different reported routes. SubQ means beneath the skin; IM means into muscle. The existing record describes both injectable research-vial use and debated site injections. It contains no established oral or topical route for these physique goals. LR3 and IGF-1 DES are different analogues, not interchangeable forms.
IGF-1 LR3 is a modified growth-factor research protein discussed for muscle fullness, growth and recovery. Reports range from noticeable pumps to no benefit; human exposure and safety remain uncertain.
Timing and local injection claims remain contested. Users favor post-workout, pre-workout or meal-time use. MESO-Rx asks whether IM gives local growth; the discussions do not establish that either route confines activity to one muscle. IGF1 LR3 (Secondhand community claim · Accessed 2026-09-30) · Has anyone taken IGF1-Lr3? (Personal report · Accessed 2026-09-30)
Source context — Human IGF-I LR3 Recombinant Protein, PeproTech: Commercial laboratory manufacturer. Identity description supports defined reagent chemistry, not retail-vial authentication or human effectiveness. Unquantified increased-half-life wording is not accepted as human PK.
Source context — IGF1 LR3: Half-life, dose bands and local growth are claims/questions, not measurements; later pages not inspected. No attribution of an intended split schedule as a completed experiment.
Source context — Has anyone taken IGF1-Lr3?: Short subjective account; no product assay, defined training endpoint or glucose measurements; no claim that blood-sugar use was effective.
What people notice
| Fullness, pumps and soreness | Some report fuller muscles, pumps or less soreness. A pump does not measure new muscle. |
|---|---|
| Growth and recovery claims | Accounts include strength, size retention on cuts and the feeling that food supports training better. Training, food, water retention and other compounds also change those outcomes. |
| Painful pumps or no change | One stacked account had intense, painful pumps but disappointing fullness. Other users reported no specific change after a couple of weeks or no value after three weeks. |
Notes
Fullness, pumps and less soreness. Canadian Brawn reports range from fullness or reduced soreness to nothing. A pump does not measure new muscle. What results did you see from cheap igf1? Des or lr3 (Community discussion · Accessed 2026-09-30)
Size, recovery and nutrient-partitioning claims. The existing community account includes strength, size retention on cuts, and the feeling that food supports training better. Food intake, training, water retention and other compounds complicate those comparisons. Satellite-cell and hyperplasia talk—making more muscle fibres—remains an explanation people circulate, not demonstrated human fibre-count gains.
Pumps can coexist with disappointing overall results. A 2026 Eroids reply reported intense, painful pumps but disappointment with fullness during multiple-compound use. The surrounding thread is seller-led, which matters when interpreting its confident benefit claims. My experience and recommendations with IGF1-lr3 protocols (Community discussion · Accessed 2026-09-30)
Some users notice nothing after weeks. A Reddit user reported no specific change after a couple of weeks at 30 mcg once daily near lunch. A 2026 respondent found no value after three weeks, without giving an amount. Has anyone taken IGF1-Lr3? (Personal report · Accessed 2026-09-30) · IGF1-LR3 for muscle building: has anyone tried it? (Community discussion · Accessed 2026-09-30)
Source context — What results did you see from cheap igf1? Des or lr3: Retrospective unverified reports; no standard measurement or authenticated product. DES-specific hypoglycemia and pump story must not be attributed to LR3.
Source context — My experience and recommendations with IGF1-lr3 protocols: Commercial author explicitly discusses customers and sales; forum replies do not neutralize promotion. Claims of cortisol abolition, proven hyperplasia and safe amounts rejected. Visible author/reply dates distinguished.
Source context — Has anyone taken IGF1-Lr3?: Short subjective account; no product assay, defined training endpoint or glucose measurements; no claim that blood-sugar use was effective.
Source context — IGF1-LR3 for muscle building: has anyone tried it?: Small self-selected discussion; absence of symptoms is not measured absence of hypoglycemia; dose and identity unverified. General benefit assertion is not an outcome log.
Doses people talk about
| 20–30 or 30–50 mcg/day charts | Separate community charts list these bands; other tables span 10–20, 40–80 or 80–100 mcg/day. These are chart conventions, not established safe ranges. |
|---|---|
| 30, 40, then 50 mcg daily | One six-week log used each amount for two weeks, preferred 40 mcg and found little extra at 50. The injection route was unstated. |
| Higher outliers | A seller promotes 50–150 mcg/day; a separate commenter claims 200 mcg in the morning while fasting without symptoms. Neither establishes effectiveness or safety. |
| Frequency and food lore | Daily, training-day-only and split use all appear, with pre-workout, post-workout or meal-time preferences. Carbohydrate-pairing charts do not guarantee protection from low blood sugar. |
Notes
20–30 mcg/day and 30–50 mcg/day appear in community charts. The original record also includes 10–20 mcg/day in smaller/female-use discussions, 40–80 mcg/day in broader tables, and 80–100 mcg/day in aggressive reports. These are separate heuristics, not validated dose bands or safety ceilings.
One log used 30, 40 and 50 mcg once daily. Each amount lasted two weeks; the author preferred 40 mcg and reported little additional benefit at 50. The injection route was not specified. IGF-1LR3 experience (Personal report · Accessed 2026-09-30)
Higher reports disagree with those charts. A seller-authored Eroids post promotes 50–150 mcg/day. A Reddit respondent claims 200 mcg in the morning while fasting without symptoms. Neither establishes effectiveness or safety. My experience and recommendations with IGF1-lr3 protocols (Community discussion · Accessed 2026-09-30) · IGF1-LR3 for muscle building: has anyone tried it? (Community discussion · Accessed 2026-09-30)
Daily use, training days only, and split amounts all appear. Existing notes describe post-workout or morning-with-food use; other users prefer pre-workout. Food-pairing charts mention 30–50 g carbohydrate within about 30 minutes and protein in the following hour. This is lore, not guaranteed hypoglycemia protection.
Timing and local injection claims remain contested. Users favor post-workout, pre-workout or meal-time use. MESO-Rx asks whether IM gives local growth; the discussions do not establish that either route confines activity to one muscle. IGF1 LR3 (Secondhand community claim · Accessed 2026-09-30) · Has anyone taken IGF1-Lr3? (Personal report · Accessed 2026-09-30)
Source context — IGF-1LR3 experience: Self-reported unverified product; changing amounts, diet, training and tesofensine; DEXA was planned, not provided. Claimed prescription does not authenticate approval or product. Lipid units omitted.
Source context — My experience and recommendations with IGF1-lr3 protocols: Commercial author explicitly discusses customers and sales; forum replies do not neutralize promotion. Claims of cortisol abolition, proven hyperplasia and safe amounts rejected. Visible author/reply dates distinguished.
Source context — IGF1-LR3 for muscle building: has anyone tried it?: Small self-selected discussion; absence of symptoms is not measured absence of hypoglycemia; dose and identity unverified. General benefit assertion is not an outcome log.
Source context — IGF1 LR3: Half-life, dose bands and local growth are claims/questions, not measurements; later pages not inspected. No attribution of an intended split schedule as a completed experiment.
Source context — Has anyone taken IGF1-Lr3?: Short subjective account; no product assay, defined training endpoint or glucose measurements; no claim that blood-sugar use was effective.
Half-life, onset & duration
| Felt onset | One stacked 40 mcg account described first-workout fullness and low-blood-sugar-like feelings within 30 minutes. A separate log changed over weeks 1–6. |
|---|---|
| Felt duration | One post-workout account reports an all-day pump. After a separate six-week course, endurance faded within a week and tingling within days; these do not measure single-dose persistence. |
| Half-life | Not measured in humans in the saved record. Both the circulated 20–30-hour half-life and competing two-hour activity claim are unverified; rat clearance does not settle human kinetics. |
Notes
A workout sensation can precede any visible change. A January 2026 poster described fullness during the first workout but hypoglycemic feelings within 30 minutes of 40 mcg. No measured glucose result was supplied; HGH and several anabolic drugs confounded the experience. IGF 1 LR3 First experience (Personal report · Accessed 2026-09-30)
The six-week log changed in stages. Modest pumps appeared in weeks 1–2, endurance in weeks 3–4, and a fuller appearance in weeks 5–6. Diet, exercise and tesofensine co-use prevent assigning those changes solely to LR3. IGF-1LR3 experience (Personal report · Accessed 2026-09-30)
Some users notice nothing after weeks. A Reddit user reported no specific change after a couple of weeks at 30 mcg once daily near lunch. A 2026 respondent found no value after three weeks, without giving an amount. Has anyone taken IGF1-Lr3? (Personal report · Accessed 2026-09-30) · IGF1-LR3 for muscle building: has anyone tried it? (Community discussion · Accessed 2026-09-30)
An all-day pump is one reported duration. A Canadian Brawn user described it with 40 mcg after workouts, without measured exposure. What results did you see from cheap igf1? Des or lr3 (Community discussion · Accessed 2026-09-30)
After stopping, different effects can fade differently. The six-week author missed the endurance within a week, said hand tingling disappeared within days, and later described retaining modest gains while maintaining diet. This does not establish single-dose duration. IGF-1LR3 experience (Personal report · Accessed 2026-09-30)
20–30 hours is a circulated claim, not measured human LR3 kinetics. An opened MESO-Rx question repeats that number while acknowledging shorter claims. It supplies no human concentration-time study. Once-daily use does not prove a half-life. IGF1 LR3 (Secondhand community claim · Accessed 2026-09-30)
A competing two-hour activity claim is also unverified. An AnabolicMinds reply attributes it to a biochemist friend and says supporting information could not be found. That is secondhand activity lore, not a measured plasma half-life. IGF-LR3 Cycle Question/controversy (Secondhand community claim · Accessed 2026-09-30)
Less binding meant faster clearance in rat experiments. Ballard and colleagues found greater potency but faster LR3 removal than native IGF-1 in rats. Gillespie's renal-failure rat study linked altered binding to degradation and clearance. Neither establishes human half-life. Ballard et al. — IGFBP interactions, plasma clearance and IGF analogue activity (Animal context · Accessed 2026-09-30) · Gillespie et al. — CRF and clearance of IGF-I and analogues (Animal context · Accessed 2026-09-30)
Source context — IGF 1 LR3 First experience: Subjective hypoglycemic feeling without a glucose value; several anabolic drugs, HGH, nutrition and exercise confound effects; route unstated. No co-drug recipe reproduced.
Source context — IGF-1LR3 experience: Self-reported unverified product; changing amounts, diet, training and tesofensine; DEXA was planned, not provided. Claimed prescription does not authenticate approval or product. Lipid units omitted.
Source context — Has anyone taken IGF1-Lr3?: Short subjective account; no product assay, defined training endpoint or glucose measurements; no claim that blood-sugar use was effective.
Source context — IGF1-LR3 for muscle building: has anyone tried it?: Small self-selected discussion; absence of symptoms is not measured absence of hypoglycemia; dose and identity unverified. General benefit assertion is not an outcome log.
Source context — What results did you see from cheap igf1? Des or lr3: Retrospective unverified reports; no standard measurement or authenticated product. DES-specific hypoglycemia and pump story must not be attributed to LR3.
Source context — IGF1 LR3: Half-life, dose bands and local growth are claims/questions, not measurements; later pages not inspected. No attribution of an intended split schedule as a completed experiment.
Source context — IGF-LR3 Cycle Question/controversy: Planned schemes are not outcomes. Two-hour human activity and 20–30-hour lab-life assertions explicitly lack supporting evidence. Bilateral amount ambiguity not converted to a daily total.
Source context — Ballard et al. — IGFBP interactions, plasma clearance and IGF analogue activity: Abstract only, no full-text tables. Rats/cell culture, not measured human LR3 exposure or hypertrophy. Publication day is indexing metadata.
Source context — Gillespie et al. — CRF and clearance of IGF-I and analogues: Abstract only; disease-model/species mismatch; not a healthy-human half-life. Publication day is indexing metadata.
Cycles people discuss
| Reported on/off patterns | Separate accounts describe three weeks on with a month off, and 4–6 weeks on with 3–4 off; the latter used 35 mcg/day while skipping two days weekly. |
|---|---|
| Competing charts | Charts also discuss 10–14 days, 21 days or 3–6 weeks on, with various breaks. Proposed 6–8-week lower-frequency schemes are not completed logs; no reset interval is validated. |
Notes
Three weeks on/month off is one reported pattern. Canadian Brawn includes this repeated course with post-workout use. What results did you see from cheap igf1? Des or lr3 (Community discussion · Accessed 2026-09-30)
A Reddit commenter reports 4–6 weeks on, 3–4 off. They describe 35 mcg/day, skipping two days weekly; no safety conclusion follows. IGF-1LR3 experience (Personal report · Accessed 2026-09-30)
Other charts use 10–14 days, 21 days, or 3–6 weeks on. The original includes four weeks on/at least four off and 4–6 weeks on/4–6 off. Receptor-desensitization and organ-growth concerns motivate breaks; no inspected evidence validates a reset interval or safe course length.
6–8-week lower-frequency schemes also circulate. An AnabolicMinds question repeats them as possible plans, not completed outcomes. IGF-LR3 Cycle Question/controversy (Secondhand community claim · Accessed 2026-09-30)
Source context — What results did you see from cheap igf1? Des or lr3: Retrospective unverified reports; no standard measurement or authenticated product. DES-specific hypoglycemia and pump story must not be attributed to LR3.
Source context — IGF-1LR3 experience: Self-reported unverified product; changing amounts, diet, training and tesofensine; DEXA was planned, not provided. Claimed prescription does not authenticate approval or product. Lipid units omitted.
Source context — IGF-LR3 Cycle Question/controversy: Planned schemes are not outcomes. Two-hour human activity and 20–30-hour lab-life assertions explicitly lack supporting evidence. Bilateral amount ambiguity not converted to a daily total.
Stacks
| GH-pathway combinations | The saved record includes HGH, CJC/Ipamorelin, sermorelin and MK-677. Combining them with LR3 makes growth and glucose changes harder to assign to one compound. |
|---|---|
| Insulin and AAS | Both appear in advanced forum stacks. Insulin adds low-blood-sugar concern; steroid co-use also prevents isolating LR3 outcomes. |
| Recovery combinations | DES, PEG-MGF, BPC-157/TB-500 and MOTS-c appear in stack talk. The MGF-then-LR3 sequence remains a proposed mechanism, not demonstrated synergy. |
| Appetite-suppressing drugs | GLP-1 or retatrutide co-use appears in recomp discussion with concern that appetite suppression can mask early low-blood-sugar hunger cues. |
Notes
Stacks make the story harder to interpret. The existing record includes HGH, CJC/Ipamorelin, sermorelin, MK-677, insulin, AAS, DES, PEG-MGF, BPC/TB and MOTS-c. Charts even place LR3 at 40–60 mcg post-workout alongside ipamorelin 100–200 mcg and CJC no DAC 100 mcg near bedtime. These are unverified chart examples, not a recommended stack. The purported MGF-then-LR3 sequence is also mechanistic lore.
HGH + LR3: Classic “GH axis” growth/recovery stack — dual attribution confounded; more glucose and growth-pathway load. [community]
CJC-1295 (often no DAC) + Ipamorelin + LR3: Popular peptide stack — secretagogues elevating endogenous GH/IGF-1 upstream, LR3 as direct post-workout receptor hit; timing usually separated (GHS fasted AM/bed; LR3 post-workout). Sample charts often show LR3 ~40–60 mcg PWO with Ipa ~100–200 mcg and CJC no DAC ~100 mcg bed-class doses (vendor charts vary). [community]
Sermorelin / other GHRH: Alternate upstream GH pulse support when CJC is not used. [community]
MK-677 + LR3: Oral GH-secretagogue + direct IGF analog — appetite/water from MK plus LR3 hypo risk; confounded recomp talk. [community]
Insulin + LR3 (advanced, high-risk): Nutrient-partitioning lore in hardcore forums; additive hypoglycemia — widely flagged as not beginner and often treated as avoid-outside-supervision. [community]
AAS bulks: LR3 layered onto steroid cycles in advanced camps; sides, source quality, and multi-drug confounds dominate. [community]
Feeling fine does not settle glucose risk. The fasting/no-symptom claim conflicts with symptomatic reports. Original notes describe shakiness, sweating, hunger, lightheadedness and confusion around 30–90 minutes. Normal fasting glucose/A1C can miss a brief event. Insulin combinations and appetite-suppressing stacks add concern. IGF1-LR3 for muscle building: has anyone tried it? (Community discussion · Accessed 2026-09-30)
PEG-MGF + LR3: “Two-wave” recovery lore — PEG-MGF soon post-workout for early satellite-cell talk, LR3 hours later for differentiation/protein-synthesis talk; schedules vary and evidence is community-level. [community]
DES + LR3: Local short DES site shots plus systemic LR3 — complexity and glucose risk stack; not a starter protocol. [community]
BPC-157 (± TB-500): Recovery/soft-tissue support alongside LR3 hypertrophy blocks — different pathways; credit split. [community]
MOTS-c discussion: Some modern stack guides pair mitochondrial/insulin-sensitivity talk with LR3 to “buffer” metabolic stress — still research-chem lore. [community]
GLP-1 / retatrutide caution: Appetite suppression can mask early hypo hunger cues; community says extra glucose vigilance if combined for recomp. [community]
Source context — IGF1-LR3 for muscle building: has anyone tried it?: Small self-selected discussion; absence of symptoms is not measured absence of hypoglycemia; dose and identity unverified. General benefit assertion is not an outcome log.
Watch for
| Low-blood-sugar symptoms | Reports include shakiness, sweating, hunger, lightheadedness and confusion around 30–90 minutes. Feeling fine or having normal fasting glucose/A1C does not rule out a brief event. |
|---|---|
| Water, hands and lipids | One log reports water retention, sore or tingling hands and higher total cholesterol and LDL. These are personal observations, not adverse-event rates. |
| Unwanted growth concerns | Waist-expansion stories do not diagnose organ growth. Mecasermin warnings about severe hypoglycemia, intracranial pressure, lymphoid enlargement and malignancy are separate context, not quantified LR3 risks. |
| Urgent symptoms | Seizure, collapse, confusion or severe headache with visual changes warrant urgent evaluation. |
| Vial identity and tested sport | Ordinary IGF-1 tests or injection burning do not authenticate LR3. WADA's saved 2026 list prohibits IGF-1 analogues at all times; forum half-lives do not establish testing clearance. |
Notes
Feeling fine does not settle glucose risk. The fasting/no-symptom claim conflicts with symptomatic reports. Original notes describe shakiness, sweating, hunger, lightheadedness and confusion around 30–90 minutes. Normal fasting glucose/A1C can miss a brief event. Insulin combinations and appetite-suppressing stacks add concern. IGF1-LR3 for muscle building: has anyone tried it? (Community discussion · Accessed 2026-09-30)
Water retention, hand soreness and tingling appear in a log. The six-week author also reported total cholesterol rising 201→221 and LDL 110→128; units were unstated. Fasting glucose/A1C reportedly stayed normal. These are individual observations, not LR3 adverse-event rates. IGF-1LR3 experience (Personal report · Accessed 2026-09-30)
Growth-factor concerns extend beyond muscles. Community waist-expansion and unwanted-growth concerns do not diagnose organ growth. Mecasermin labeling separately warns about severe hypoglycemia, intracranial hypertension, lymphoid enlargement and malignancy; it does not quantify LR3 risk. INCRELEX prescribing information (Official context · Accessed 2026-09-30)
Severe symptoms need urgent evaluation. Seizure, collapse, confusion, or severe headache with visual changes warrant urgent care. INCRELEX prescribing information (Official context · Accessed 2026-09-30)
Symptoms and ordinary IGF-1 blood tests do not authenticate a vial. Community explanations for no response include identity, handling, training and food, but none alone identifies the cause. The existing account cautions that native IGF-1 assays may not reflect LR3 exposure, and GH feedback complicates interpretation. Its acetic-acid versus water debate is preserved as handling disagreement; burning is not evidence of potency. Vial labels cannot guarantee identity, purity or sterility.
Tested sport: prohibited at all times. WADA's 2026 S2.3 list includes IGF-1 and its analogues. Forum half-life numbers cannot establish a drug-test clearance window. WADA 2026 Prohibited List (Official context · Accessed 2026-09-30)
Source context — IGF1-LR3 for muscle building: has anyone tried it?: Small self-selected discussion; absence of symptoms is not measured absence of hypoglycemia; dose and identity unverified. General benefit assertion is not an outcome log.
Source context — IGF-1LR3 experience: Self-reported unverified product; changing amounts, diet, training and tesofensine; DEXA was planned, not provided. Claimed prescription does not authenticate approval or product. Lipid units omitted.
Source context — INCRELEX prescribing information: Native recombinant IGF-1/mecasermin for pediatric disease, not LR3 or an adult bodybuilding safety trial. No label dose, risk rate or half-life transferred to community quick answers.
Source context — WADA 2026 Prohibited List: Anti-doping classification, not general legal status or pharmacokinetic detection window.
Full notes
IGF-1 LR3 is a modified growth-factor research protein discussed for muscle fullness, growth and recovery. Reports range from noticeable pumps to no benefit; human exposure and safety remain uncertain.
What IGF-1 LR3 is
- An altered 83-amino-acid IGF-1 protein. Native IGF-1 has 70 amino acids. LR3 adds 13 and changes the third to arginine. A laboratory reagent or physique-use vial is different from prescription mecasermin and HGH. Official context Community
- Direct growth-factor activity is the appeal. Communities contrast LR3 with HGH, MK-677 and GH-releasing peptides, which influence the body's GH/IGF pathway. Reduced binding to IGF-binding proteins changes laboratory activity; it does not establish selective muscle growth or long human circulation. Community Animal context
- SubQ and IM are different reported routes. SubQ means beneath the skin; IM means into muscle. The existing record describes both injectable research-vial use and debated site injections. It contains no established oral or topical route for these physique goals. LR3 and IGF-1 DES are different analogues, not interchangeable forms. Community
Benefits people seek and describe
- Fullness, pumps and less soreness. Canadian Brawn reports range from fullness or reduced soreness to nothing. A pump does not measure new muscle. Canadian Brawn
- Size, recovery and nutrient-partitioning claims. The existing community account includes strength, size retention on cuts, and the feeling that food supports training better. Food intake, training, water retention and other compounds complicate those comparisons. Satellite-cell and hyperplasia talk—making more muscle fibres—remains an explanation people circulate, not demonstrated human fibre-count gains. Community
Doses people discuss
Reported injection amounts, not a regimen. mcg means micrograms; 1,000 mcg equals 1 mg. A vial's labeled amount does not verify its contents.
- 20–30 mcg/day and 30–50 mcg/day appear in community charts. The original record also includes 10–20 mcg/day in smaller/female-use discussions, 40–80 mcg/day in broader tables, and 80–100 mcg/day in aggressive reports. These are separate heuristics, not validated dose bands or safety ceilings. Community
- One log used 30, 40 and 50 mcg once daily. Each amount lasted two weeks; the author preferred 40 mcg and reported little additional benefit at 50. The injection route was not specified. Personal report
- Higher reports disagree with those charts. A seller-authored Eroids post promotes 50–150 mcg/day. A Reddit respondent claims 200 mcg in the morning while fasting without symptoms. Neither establishes effectiveness or safety. Eroids Reddit r/Peptidesource
- Daily use, training days only, and split amounts all appear. Existing notes describe post-workout or morning-with-food use; other users prefer pre-workout. Food-pairing charts mention 30–50 g carbohydrate within about 30 minutes and protein in the following hour. This is lore, not guaranteed hypoglycemia protection. Community Community
Half-life
- 20–30 hours is a circulated claim, not measured human LR3 kinetics. An opened MESO-Rx question repeats that number while acknowledging shorter claims. It supplies no human concentration-time study. Once-daily use does not prove a half-life. MESO-Rx
- A competing two-hour activity claim is also unverified. An AnabolicMinds reply attributes it to a biochemist friend and says supporting information could not be found. That is secondhand activity lore, not a measured plasma half-life. AnabolicMinds
Onset: when people notice something
- A workout sensation can precede any visible change. A January 2026 poster described fullness during the first workout but hypoglycemic feelings within 30 minutes of 40 mcg. No measured glucose result was supplied; HGH and several anabolic drugs confounded the experience. Personal report
- The six-week log changed in stages. Modest pumps appeared in weeks 1–2, endurance in weeks 3–4, and a fuller appearance in weeks 5–6. Diet, exercise and tesofensine co-use prevent assigning those changes solely to LR3. Personal report
- Some users notice nothing after weeks. A Reddit user reported no specific change after a couple of weeks at 30 mcg once daily near lunch. A 2026 respondent found no value after three weeks, without giving an amount. Personal report Reddit r/Peptidesource
Duration: how long reported effects last
- An all-day pump is one reported duration. A Canadian Brawn user described it with 40 mcg after workouts, without measured exposure. Canadian Brawn
- After stopping, different effects can fade differently. The six-week author missed the endurance within a week, said hand tingling disappeared within days, and later described retaining modest gains while maintaining diet. This does not establish single-dose duration. Personal report
Cycles and time off
- Three weeks on/month off is one reported pattern. Canadian Brawn includes this repeated course with post-workout use. Canadian Brawn
- A Reddit commenter reports 4–6 weeks on, 3–4 off. They describe 35 mcg/day, skipping two days weekly; no safety conclusion follows. Personal report
- Other charts use 10–14 days, 21 days, or 3–6 weeks on. The original includes four weeks on/at least four off and 4–6 weeks on/4–6 off. Receptor-desensitization and organ-growth concerns motivate breaks; no inspected evidence validates a reset interval or safe course length. Community
- 6–8-week lower-frequency schemes also circulate. An AnabolicMinds question repeats them as possible plans, not completed outcomes. AnabolicMinds
Cautions that matter
- Feeling fine does not settle glucose risk. The fasting/no-symptom claim conflicts with symptomatic reports. Original notes describe shakiness, sweating, hunger, lightheadedness and confusion around 30–90 minutes. Normal fasting glucose/A1C can miss a brief event. Insulin combinations and appetite-suppressing stacks add concern. Reddit r/Peptidesource Community
- Water retention, hand soreness and tingling appear in a log. The six-week author also reported total cholesterol rising 201→221 and LDL 110→128; units were unstated. Fasting glucose/A1C reportedly stayed normal. These are individual observations, not LR3 adverse-event rates. Personal report
- Growth-factor concerns extend beyond muscles. Community waist-expansion and unwanted-growth concerns do not diagnose organ growth. Mecasermin labeling separately warns about severe hypoglycemia, intracranial hypertension, lymphoid enlargement and malignancy; it does not quantify LR3 risk. Community Official context
- Severe symptoms need urgent evaluation. Seizure, collapse, confusion, or severe headache with visual changes warrant urgent care. Community Official context
- Food, bedtime and medical conditions remain watch-fors. Charts discourage fasting, bedtime dosing and doubling missed amounts; some specify 2–3 hours before sleep. Those rules do not establish safety. Pregnancy, diabetes, organ disease, swelling, headache and joint aches remain concerns in the original discussion. Community Community Community
- Tested sport: prohibited at all times. WADA's 2026 S2.3 list includes IGF-1 and its analogues. Forum half-life numbers cannot establish a drug-test clearance window. Official context
What community experience adds
- More micrograms did not fix one user's disappointment. Husky1 on MuscleChemistry described no visible side-to-side difference and only more burning after increasing 50→120 mcg. Another member reported weight gain while tapering anabolic drugs. That exchange preserves disagreement without proving local growth or blaming nonresponse on a fake vial. MuscleChemistry
- Timing and local injection claims remain contested. Users favor post-workout, pre-workout or meal-time use. MESO-Rx asks whether IM gives local growth; the discussions do not establish that either route confines activity to one muscle. Community MESO-Rx Personal report
- Pumps can coexist with disappointing overall results. A 2026 Eroids reply reported intense, painful pumps but disappointment with fullness during multiple-compound use. The surrounding thread is seller-led, which matters when interpreting its confident benefit claims. Eroids
- Stacks make the story harder to interpret. The existing record includes HGH, CJC/Ipamorelin, sermorelin, MK-677, insulin, AAS, DES, PEG-MGF, BPC/TB and MOTS-c. Charts even place LR3 at 40–60 mcg post-workout alongside ipamorelin 100–200 mcg and CJC no DAC 100 mcg near bedtime. These are unverified chart examples, not a recommended stack. The purported MGF-then-LR3 sequence is also mechanistic lore. Community
- Symptoms and ordinary IGF-1 blood tests do not authenticate a vial. Community explanations for no response include identity, handling, training and food, but none alone identifies the cause. The existing account cautions that native IGF-1 assays may not reflect LR3 exposure, and GH feedback complicates interpretation. Its acetic-acid versus water debate is preserved as handling disagreement; burning is not evidence of potency. Vial labels cannot guarantee identity, purity or sterility. Community Community
Context behind the long-acting claim
- Less binding meant faster clearance in rat experiments. Ballard and colleagues found greater potency but faster LR3 removal than native IGF-1 in rats. Gillespie's renal-failure rat study linked altered binding to degradation and clearance. Neither establishes human half-life. Animal context Animal context